EE515 Cost Per Responder Analysis of Methotrexate Versus Other Therapies in the Treatment of Moderate to Severe Plaque Psoriasis in Italy

Abstract

Conventional synthetic disease modifying antirheumatic drugs (csDMARDs) was recommended in 2019 as first line therapy from Italian Drug Agency (AIFA) for the treatment of moderate to severe psoriasis. Updated local guidelines recommended methotrexate (MTX) as the drug of first choice. Nevertheless, MTX is reported by AIFA to be underused. Since no study evaluated jointly the first-line efficacy and costs of the most widely used biologic/biosimilar drugs (adalimumab, etanercept, secukinumab and ustekinumab) and methotrexate in Italy, a cost per responder analysis was performed.